Palonosetron and Blood Coagulation
Primary Purpose
Blood Coagulation Disorder
Status
Recruiting
Phase
Not Applicable
Locations
Korea, Republic of
Study Type
Interventional
Intervention
0 ul of palonosetron
1 ul of palonosetron
10 ul of palonosetron
100 ul of palonosetron
Sponsored by
About this trial
This is an interventional basic science trial for Blood Coagulation Disorder
Eligibility Criteria
Inclusion Criteria:
- Healthy volunteers
- Age: 20 to 65 years
- Body weight > 50 kg
- Volunteers who provided informed consent
Exclusion Criteria:
- Hematologic disease
- Anticoagulant medication
Sites / Locations
- Seoul National Univ. Bundang HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Experimental
Arm Label
0 ng/ml
25 ng/ml
250 ng/ml
2500 ng/ml
Arm Description
Blood specimen which was added of 0 ul of palonosetron
Blood specimen which was added of 1 ul of palonosetron
Blood specimen which was added of 10 ul of palonosetron
Blood specimen which was added of 100 ul of palonosetron
Outcomes
Primary Outcome Measures
Citrated Functional Fibrinogen
Provides clot strength based on fibrinogen contribution
Secondary Outcome Measures
Citrated Kaolin
Normal thromboelastography
Citrated Kaolin Heparinase
To assess the effect of heparin
Citrated Rapid Thromboelastography
A quicker assessment of clot strength, without assessment of clot initiation
Heparinized Kaloin Heprinase
To measure the platelet function
Activator F
To elimitate the platelt function
Adenosine diphosphate
To measure the drug effect
Arachidonic acid
To measure the drug effect
Full Information
NCT ID
NCT04507711
First Posted
July 31, 2020
Last Updated
March 13, 2023
Sponsor
Seoul National University Bundang Hospital
1. Study Identification
Unique Protocol Identification Number
NCT04507711
Brief Title
Palonosetron and Blood Coagulation
Official Title
The Effect of a Palonosetron on Blood Coagulation: In Vitro, Volunteer Study Using Thromboelastography
Study Type
Interventional
2. Study Status
Record Verification Date
March 2023
Overall Recruitment Status
Recruiting
Study Start Date
September 16, 2020 (Actual)
Primary Completion Date
November 15, 2023 (Anticipated)
Study Completion Date
December 15, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Seoul National University Bundang Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Palonosetron may alter whole blood coagulation. However, little is known about the dose-response relationships according to the blood concentration of palonosetron. The investigators therefore will perform the present study to measure the effect of palonosetron levels using thromboelastography.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Blood Coagulation Disorder
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
12 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
0 ng/ml
Arm Type
Experimental
Arm Description
Blood specimen which was added of 0 ul of palonosetron
Arm Title
25 ng/ml
Arm Type
Experimental
Arm Description
Blood specimen which was added of 1 ul of palonosetron
Arm Title
250 ng/ml
Arm Type
Experimental
Arm Description
Blood specimen which was added of 10 ul of palonosetron
Arm Title
2500 ng/ml
Arm Type
Experimental
Arm Description
Blood specimen which was added of 100 ul of palonosetron
Intervention Type
Drug
Intervention Name(s)
0 ul of palonosetron
Intervention Description
Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (0 ul) using palonosetron
Intervention Type
Drug
Intervention Name(s)
1 ul of palonosetron
Intervention Description
Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (1 ul) using palonosetron
Intervention Type
Drug
Intervention Name(s)
10 ul of palonosetron
Intervention Description
Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (10 ul) using palonosetron
Intervention Type
Drug
Intervention Name(s)
100 ul of palonosetron
Intervention Description
Venous blood is taken from 11 healthy volunteers and divided into four specimen bottles, which were added with different doses (100 ul) using palonosetron
Primary Outcome Measure Information:
Title
Citrated Functional Fibrinogen
Description
Provides clot strength based on fibrinogen contribution
Time Frame
During the thromboelastography analysis/ an average of 1 hour
Secondary Outcome Measure Information:
Title
Citrated Kaolin
Description
Normal thromboelastography
Time Frame
During the thromboelastography analysis/ an average of 1 hour
Title
Citrated Kaolin Heparinase
Description
To assess the effect of heparin
Time Frame
During the thromboelastography analysis/ an average of 1 hour
Title
Citrated Rapid Thromboelastography
Description
A quicker assessment of clot strength, without assessment of clot initiation
Time Frame
During the thromboelastography analysis/ an average of 1 hour
Title
Heparinized Kaloin Heprinase
Description
To measure the platelet function
Time Frame
During the thromboelastography analysis/ an average of 1 hour
Title
Activator F
Description
To elimitate the platelt function
Time Frame
During the thromboelastography analysis/ an average of 1 hour
Title
Adenosine diphosphate
Description
To measure the drug effect
Time Frame
During the thromboelastography analysis/ an average of 1 hour
Title
Arachidonic acid
Description
To measure the drug effect
Time Frame
During the thromboelastography analysis/ an average of 1 hour
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Healthy volunteers
Age: 20 to 65 years
Body weight > 50 kg
Volunteers who provided informed consent
Exclusion Criteria:
Hematologic disease
Anticoagulant medication
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Hyo-Seok Na, MD., PhD.
Phone
82317877507
Email
hsknana@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hyo-Seok Na, MD., PhD.
Organizational Affiliation
Seoul National University Bundang Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Seoul National Univ. Bundang Hospital
City
Seongnam
State/Province
Gyeonggi
ZIP/Postal Code
463-707
Country
Korea, Republic of
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hyo-Seok Na
Phone
1087012913
Email
hsknana@gmail.com
12. IPD Sharing Statement
Learn more about this trial
Palonosetron and Blood Coagulation
We'll reach out to this number within 24 hrs